Genetic Risk Factors Associated with the Prognosis of Myocardial Infarction in Young Patients

Yi-Heng Li; Jyh-Hong Chen; How-Ran Guo; Wei-Chuan Tsai; Ting-Hsing Chao

doi:10.1055/s-0037-1613282

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 88(04): 694-697
DOI: 10.1055/s-0037-1613282

Letters to the Editor

Schattauer GmbH

Genetic Risk Factors Associated with the Prognosis of Myocardial Infarction in Young Patients

Authors

Yi-Heng Li

¹Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
Jyh-Hong Chen

¹Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
How-Ran Guo

¹Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
Wei-Chuan Tsai

¹Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
Ting-Hsing Chao

¹Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan

Abstract

Full Text

References

References
1 DeWood MA, Spores J, Notske RN. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
2 Anderson JL, King GJ, Bair TL. et al. Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction and coronary artery disease. J Am Coll Cardiol 1999; 33: 727-33.
3 Margaglione M, Grandone E, Cappucci G. et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997; 77: 605.
4 Green F, Kelleher C, Wilkes H. et al. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
5 Li YH, Chen JH, Tsai WC. et al. Synergistic effect of thrombomodulin promoter -33G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Haemost 2002; 87: 86-91.
6 Frosst P, Blom HJ, Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
7 Wang LX, Sim AS, Badenhop RF. et al. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996; 02: 41-5.
8 Tanaka S, Ohnoki S, Shibata H. et al. Gene frequencies of human platelet antigens on glycoprotein IIIa in Japanese. Transfusion 1996; 36: 813-7.
9 Hato T, Minamoto Y, Fukuyama T. et al. Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol 1997; 80: 1222-4.
10 Herrmann SM, Poirier O, Marques-Vidal P. et al. The Leu33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GP IIIa) receptor is not related to myocardial infarction in the ECTIM study. Thromb Haemost 1997; 77: 1179-81.
11 Ridker PM, Hennekens CH, Schmitz C. et al. PlA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet 1997; 349: 385-8.
12 Ardissino D, Mannucci PM, Merlini PA. et al. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
13 Iwai N, Shimoike H, Nakamura Y. et al. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes. Atherosclerosis 1998; 136: 109-14.
14 Song J, Yoon YM, Jung HJ. et al. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353 → Gln polymorphism in Korean patients with coronary artery disease. J Korean Med Sci 2000; 15: 146-52.
15 Ye S, Green FR, Scarabin PY. et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.
16 Ridker PM, Hennekens CH, Lindpaintner K. et al. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
17 Tamaki S, Iwai N, Nakamura Y. et al. Variation of the factor VII gene and ischemic heart disease in Japanese subjects. Coronary Artery Disease 1999; 10: 601-6.
18 Lane A, Green F, Scarabin PY. et al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indication of MI risk in ECTIM study. Atherosclerosis 1996; 119: 119-27.
19 Doggen CJM, Manger VCats, Bertina RM. et al. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-5.
20 Ireland H, Kunz G, Kyriakoulis K. et al. Thrombomodulin gene mutations associated with myocardial infarction. Circulation 1997; 96: 15-8.
21 Le Flem L, Picard V, Emmerich J. et al. Mutations in promoter region of thrombomodulin and venous thromboembolic disease. Arterioscler Thromb Vasc Biol 1999; 19: 1098-104.